- Home
- WLAC vs MDXH Comparison
WLAC vs MDXH Comparison
Compare WLAC & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLAC
- MDXH
- Stock Information
- Founded
- WLAC 2024
- MDXH 2003
- Country
- WLAC United States
- MDXH Belgium
- Employees
- WLAC N/A
- MDXH N/A
- Industry
- WLAC
- MDXH
- Sector
- WLAC
- MDXH
- Exchange
- WLAC Nasdaq
- MDXH Nasdaq
- Market Cap
- WLAC 215.3M
- MDXH 203.4M
- IPO Year
- WLAC 2024
- MDXH 2021
- Fundamental
- Price
- WLAC $12.63
- MDXH $4.14
- Analyst Decision
- WLAC
- MDXH Buy
- Analyst Count
- WLAC 0
- MDXH 1
- Target Price
- WLAC N/A
- MDXH $6.00
- AVG Volume (30 Days)
- WLAC 923.3K
- MDXH 185.6K
- Earning Date
- WLAC 01-01-0001
- MDXH 11-05-2025
- Dividend Yield
- WLAC N/A
- MDXH N/A
- EPS Growth
- WLAC N/A
- MDXH N/A
- EPS
- WLAC N/A
- MDXH N/A
- Revenue
- WLAC N/A
- MDXH $98,953,000.00
- Revenue This Year
- WLAC N/A
- MDXH $24.43
- Revenue Next Year
- WLAC N/A
- MDXH $21.00
- P/E Ratio
- WLAC $933.68
- MDXH N/A
- Revenue Growth
- WLAC N/A
- MDXH 22.56
- 52 Week Low
- WLAC $9.80
- MDXH $1.35
- 52 Week High
- WLAC $15.19
- MDXH $4.94
- Technical
- Relative Strength Index (RSI)
- WLAC N/A
- MDXH 49.40
- Support Level
- WLAC N/A
- MDXH $3.86
- Resistance Level
- WLAC N/A
- MDXH $4.40
- Average True Range (ATR)
- WLAC 0.00
- MDXH 0.24
- MACD
- WLAC 0.00
- MDXH -0.11
- Stochastic Oscillator
- WLAC 0.00
- MDXH 24.49
About WLAC Willow Lane Acquisition Corp. Class A Ordinary Shares
Willow Lane Acquisition Corp is a blank check company.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.